Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $20.2 million.

  • Cytek Biosciences' Accumulated Expenses fell 241.16% to $20.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.2 million, marking a year-over-year decrease of 241.16%. This contributed to the annual value of $21.4 million for FY2024, which is 702.77% up from last year.
  • Latest data reveals that Cytek Biosciences reported Accumulated Expenses of $20.2 million as of Q3 2025, which was down 241.16% from $21.6 million recorded in Q2 2025.
  • Cytek Biosciences' Accumulated Expenses' 5-year high stood at $21.6 million during Q2 2025, with a 5-year trough of $10.8 million in Q3 2021.
  • Moreover, its 5-year median value for Accumulated Expenses was $19.4 million (2023), whereas its average is $18.1 million.
  • As far as peak fluctuations go, Cytek Biosciences' Accumulated Expenses skyrocketed by 6855.66% in 2021, and later crashed by 2093.82% in 2024.
  • Cytek Biosciences' Accumulated Expenses (Quarter) stood at $15.3 million in 2021, then soared by 38.52% to $21.1 million in 2022, then decreased by 5.16% to $20.0 million in 2023, then rose by 7.03% to $21.4 million in 2024, then decreased by 5.64% to $20.2 million in 2025.
  • Its Accumulated Expenses stands at $20.2 million for Q3 2025, versus $21.6 million for Q2 2025 and $19.2 million for Q1 2025.